These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

101 related articles for article (PubMed ID: 3150281)

  • 1. Valproic acid pharmacokinetics in children: III. Very high dosage requirements.
    Kriel RL; Fischer JH; Cloyd JC; Green KH; Fraser GL
    Pediatr Neurol; 1986; 2(4):202-8. PubMed ID: 3150281
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A single daily dose with valproic acid. A pharmacodynamic and clinical study].
    Pelzl G; Mamoli B
    Wien Klin Wochenschr; 1992; 104(10):286-9. PubMed ID: 1604872
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Serum valproate concentrations in epileptic children with favourable responses.
    Ishikawa T; Ogino C; Furuyama M; Kanayama M; Awaya A; Yamaguchi A
    Brain Dev; 1987; 9(3):283-7. PubMed ID: 3116876
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic parameters of total and unbound valproic acid and their relationships to seizure control in epileptic children.
    Panomvana Na Ayudhya D; Suwanmanee J; Visudtibhan A
    Am J Ther; 2006; 13(3):211-7. PubMed ID: 16772762
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of valproic acid in children: I. Multiple antiepileptic drug therapy.
    Cloyd JC; Kriel RL; Fischer JH; Sawchuk RJ; Eggerth RM
    Neurology; 1983 Feb; 33(2):185-91. PubMed ID: 6401848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Valproic acid dosages necessary to maintain therapeutic concentrations in children.
    Suzuki Y; Cox S; Hayes J; Walson PD
    Ther Drug Monit; 1991 Jul; 13(4):314-7. PubMed ID: 1780963
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [The pharmacokinetic optimization of depakin in children with epilepsy].
    Shamansurov ShSh
    Zh Nevrol Psikhiatr Im S S Korsakova; 1994; 94(6):37-8. PubMed ID: 7740873
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Valproic acid pharmacokinetics in children. IV. Effects of age and antiepileptic drugs on protein binding and intrinsic clearance.
    Cloyd JC; Fischer JH; Kriel RL; Kraus DM
    Clin Pharmacol Ther; 1993 Jan; 53(1):22-9. PubMed ID: 8422737
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A population pharmacokinetic model of valproic acid in pediatric patients with epilepsy: a non-linear pharmacokinetic model based on protein-binding saturation.
    Ding J; Wang Y; Lin W; Wang C; Zhao L; Li X; Zhao Z; Miao L; Jiao Z
    Clin Pharmacokinet; 2015 Mar; 54(3):305-17. PubMed ID: 25388986
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetic study of slow-release preparation of sodium valproate (KW-6066N): multiple dose administration test and the steady-state serum level profiles in epileptic patients.
    Takeda A; Hishida H; Amioka K; Sakamoto Y; Terao S; Ishikawa S; Aoki H
    Jpn J Psychiatry Neurol; 1989 Sep; 43(3):515-6. PubMed ID: 2516565
    [No Abstract]   [Full Text] [Related]  

  • 11. Valproic acid pharmacokinetics in children. II. Discontinuation of concomitant antiepileptic drug therapy.
    Cloyd JC; Kriel RL; Fischer JH
    Neurology; 1985 Nov; 35(11):1623-7. PubMed ID: 3932898
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Valproic acid clearance in children with epilepsy.
    Sánchez-Alcaraz A; Quintana MB; López E; Rodríguez I
    J Clin Pharm Ther; 1998 Feb; 23(1):31-4. PubMed ID: 9756109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High-dose sodium valproate therapy for childhood refractory epilepsy.
    Amano R; Mizukawa M; Ohtsuka Y; Ohtahara S
    Jpn J Psychiatry Neurol; 1990 Jun; 44(2):343-4. PubMed ID: 2124287
    [No Abstract]   [Full Text] [Related]  

  • 14. Steady-state pharmacokinetic simulation of intermittent vs. continuous infusion valproic acid therapy in non-critically ill and critically ill patients.
    Van Matre ET; Cook AM
    Neurol Res; 2016 Sep; 38(9):786-91. PubMed ID: 27414414
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum concentrations of rufinamide in children and adults with epilepsy: the influence of dose, age, and comedication.
    May TW; Boor R; Rambeck B; Jürgens U; Korn-Merker E; Brandt C
    Ther Drug Monit; 2011 Apr; 33(2):214-21. PubMed ID: 21383651
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lamotrigine-valproic acid combination therapy for medically refractory epilepsy.
    Moeller JJ; Rahey SR; Sadler RM
    Epilepsia; 2009 Mar; 50(3):475-9. PubMed ID: 19054403
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Valproic acid blood genomic expression patterns in children with epilepsy - a pilot study.
    Tang Y; Glauser TA; Gilbert DL; Hershey AD; Privitera MD; Ficker DM; Szaflarski JP; Sharp FR
    Acta Neurol Scand; 2004 Mar; 109(3):159-68. PubMed ID: 14763951
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Developmental and therapeutic pharmacology of antiepileptic drugs.
    Miura H
    Epilepsia; 2000; 41 Suppl 9():2-6. PubMed ID: 11156504
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral rapid loading of valproic acid--an alternative to the usual saturation scheme?
    Gerstner T; Bell N; Longin E; König SA
    Seizure; 2006 Dec; 15(8):630-2. PubMed ID: 17070075
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of age and co-medication on the steady-state pharmacokinetics of valproic acid in Tunisian patients with epilepsy.
    Ben Mahmoud L; Hakim A; Ghozzi H; Atheymen R; Sahnoun Z; Zeghal K
    Rev Neurol (Paris); 2017 Mar; 173(3):159-163. PubMed ID: 28320517
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.